Size-dependent release of carboxyfluorescein from cetylmannoside-modified liposomes in human plasma

Biopharmaceutics and Drug Disposition

Volumn 17, Issue 2, 1996, Pages 145-154

  Ferdous, Abu Jamil ^a,b   Ishida, Tatsuhiro ^a   Shinohara, Mika ^a   Harashima, Hideyoshi ^a   Kiwada, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

C3; Complement; DDS; ELISA; Human; Liposomes; Mannose; Opsonins; Plasma; Release; Size

Indexed keywords

CARBOXYFLUORESCEIN; CETYLMANNOSIDE; COMPLEMENT COMPONENT C3; LIPOSOME; UNCLASSIFIED DRUG;

ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; PARTICLE SIZE;

DRUG CARRIERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EVALUATION STUDIES; FLUORESCEINS; FLUORESCENT DYES; HUMANS; LIPOSOMES; MANNOSIDES; METABOLIC CLEARANCE RATE; PARTICLE SIZE; PHAGOCYTOSIS;

EID: 0029882165     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199603)17:2<145::AID-BDD942>3.0.CO;2-Y     Document Type: Article

References (22)

1. G. Gregoriadis and C. Davis, Stability of liposomes in vivo and in vitro is promoted by their cholesterol content and the presence of blood cells. Biochem. Biophys. Res. Commun., 89, 1287-1293 (1979).
2. G. Scherphof, G. Roerdink, M. Waite and J. Parks, Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins. Biochim. Biophys. Acta, 542, 296-307 (1978).
3. J. Senior and G. Gregoriadis, Is half-life of circulating small unilamellar liposomes determined by changes in their permeability? FEBS Lett, 145, 109-114 (1982).
4. T. M. Allen and J. M. Everest, Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats. J. Pharm. Exp. Ther., 226, 539-544 (1983).
5. A. Chonn, S. C. Sample and P. R. Cullis, Association of blood proteins with large unilamellar liposomes in vivo. J. Biol. Chem., 267, 18759-18765 (1992).
6. H. Harashima, K. Sakata, K. Funato and H. Kiwada, Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm. Res., 11, 402-406 (1994).
7. H. Matsuo, K. Funato, H. Harashima and H. Kiwada, The complement- but not mannose receptor mediated phagocytosis is involved in the hepatic uptake of cetylmannoside-modified liposomes in situ. J. Drug Targ., 2, 141-146 (1994).
8. K. Funato, R. Yoda and H. Kiwada, Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma. Biochim. Biophys. Acta, 1103, 198-204 (1992).
9. K. Funato, C. Yamashita, J. Kamada, S. Tominaga and H. Kiwada, Plasma factor triggering alternative complement pathway activation by liposomes. Pharm. Res., 11, 372-376 (1994).
10. H. Matsuo, C. Yamashita, K. Akiyama and H. Kiwada, Effect of cetylmannoside modification on the alternative complement pathway activation by liposomes in rat serum. Biol. Pharm. Bull., 18, 581-585 (1995).
11. H. Harashima, T. Hiraiwa, Y. Ochi and H. Kiwada, Size dependent liposome degradation in blood: in vivo/in vitro correlation by kinetic modeling. J. Drug Targ., in press.
12. T. Ishida, M. Shinohara, F. Iwata, Y. Ohmoto and H. Kiwada, Quantitative determination of C3 fragments on the liposomal surface with anti-human C3 monoclonal antibodies. Drug Delivery Syst., 9, 25-30 (1994).
13. H. Harashima, Y. Ochi and H. Kiwada, Kinetic modeling of liposome degradation in serum: effect of size and concentration of liposomes in vitro. Biopharm. Drug Disposit., 15, 217-225 (1994).
14. K. Yamaoka, Y. Tanigawara, T. Nakagawa and T. Uno, A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio-Dyn, 4, 879-885 (1981).
15. A. Kagayasu, T. Shimooka and H. Kiwada, Solubilization by Triton X-100 makes possible complete recovery of lipids from liposomes in enzymatic assay. Biochim. Biophys. Acta, 1194, 12-16 (1994).
16. D. V. Devine, K. Wong, K. Serrano, A. Chonn and P. R. Cullis. Liposome-complement interactions in rat serum: implications for liposomal survival studies. Biochem. Biophys. Acta, 1191, 43-51 (1994).
17. B. P. Morgan, Complement: the Complement System. Academic, San Diego, pp. 1-35.
18. F. Bonte and R. L. Juliano, Interaction of liposomes with serum proteins. Chem. Phys. Lipids, 40, 359-372 (1986).
19. T. Hernandez-Caselles, J. Villalain and J. C. Gomez-Fernandez, Influence of liposome charge and composition on their interaction with human blood serum proteins. Mol. Cell Biochem., 120, 119-126 (1993).
20. N. Van Rooijen and R. Van Nieuwmegen, Liposomes in immunology: multilamellar phosphatidylcholine liposomes as a simple, biodegradable and harmless adjuvant without any immunologic activity of its own. Cell Immunol., 49, 402-407 (1980).
21. J. Marjan, Z. Xie and D. V. Devine, Liposome-induced activation of the classical complement pathway does not require immunoglobulin. Biochim. Biophys. Acta, 1192, 35-44 (1994).
22. R. B. Sim and R. Malhotra, Interaction of carbohydrates and lectins with complement. Biochem. Soc. Trans., 22, 106-111 (1994).